It is important to know tumor genetic profile as genetic mutations have a fundamental impact on the selection of targeted therapy such as BRAF/MEK inhibitors in BRAF-mutated tumors, tyrosine kinase inhibitors in KIT-mutated tumors and MEK inhibitors in NRAS-mutated tumors [6]. Here, NRAS is linked to neoplasm.